HomeCOVID-19 treatment studies for Vitamin D COVID-19 treatment studies for Vitamin D C19 studies: Vitamin D Vitamin D Select treatmentSelect treatmentTreatmentsTreatments
The Effect of Vitamin D Supplementation on Severe COVID-19 Outcomes in Patients With Vitamin D Insufficiency
Levitus et al., Journal of the Endocrine Society, doi: 10.1210/jendso/bvab048.567
Levitus et al., The Effect of Vitamin D Supplementation on Severe COVID-19 Outcomes in Patients With Vitamin D Insufficiency, Journal of the Endocrine Society, doi: 10.1210/jendso/bvab048.567
Retrospective 129 hospitalized patients with vitamin D levels measured within 90 days prior to admission, showing lower, but not statistically significant, risk of severe cases with vitamin D supplementation among patients with levels <20ng/mL or <12ng/mL. For <30ng/mL, lower (but not statistically significant) risk was seen overall but not for ≥50,000IU (the sample size is not given, it may be extremely small for this case). Only minimal details for <30ng/mL are provided, and no details for <20ng/mL or <12ng/mL are provided. The potential effect of supplementation on the risk of a case severe enough for hospitalization is not included.
risk of severe case, 30.8% lower, RR 0.69, p = 0.25, treatment 65, control 64, odds ratio converted to relative risk, ≥1,000IU, control prevalence approximated with overall prevalence.
risk of severe case, 40.0% lower, RR 0.60, p = 0.15, treatment 65, control 64, odds ratio converted to relative risk, ≥5,000IU, control prevalence approximated with overall prevalence.
risk of severe case, no change, RR 1.00, p = 0.92, treatment 65, control 64, odds ratio converted to relative risk, ≥50,000IU, control prevalence approximated with overall prevalence.
Abstract: doi: 10.1210/jendso/bvab048 | Journal of the Endocrine Society | A279
aimed to determine whether vitamin D supplementation in
vitamin D insufficient patients was associated with fewer
severe COVID-19 outcomes, defined as mechanical ventilation or death. Methods: Retrospective study that analyzed
data from all adult patients admitted to our tertiary care
center between March 2020 and July 2020 with a positive
RT-PCR for SARS CoV-2 and a serum 25-hydroxyvitamin
D (25[OH]D) level measured within 90 days prior to the
index admission. Patients with 25(OH)D <30 ng/mL were
considered vitamin D insufficient and patients ordered for
least one weekly dose of ≥1,000 units of ergocalciferol or cholecalciferol were considered supplemented. Supplemented
vitamin D insufficient patients were compared to nonsupplemented vitamin D insufficient patients in terms of
severe COVID-19 disease as defined by mechanical ventilation or death. Results: 129 COVID-19 patients with a
vitamin D level <30 ng/mL were identified, with a median
vitamin D level of 21.4 ng/mL. A total of 43 patients (33.3%)
had severe COVID-19 outcomes. 65 (50.4%) patients with
vitamin D insufficiency were supplemented and 64 (49.6%)
were not supplemented. Vitamin D supplementation with
≥1,000 units (OR 0.6, 95% CI 0.28 - 1.40; p=0.25), ≥5,000
units (OR 0.5, 95% CI 0.26 - 1.23; p=0.15), or ≥50,000 units
(OR 1.0, 95% CI 0.42–2.20, p=0.92) weekly had no statistically significant effect on severe COVID-19 outcomes.
The odds of severe COVID-19 outcomes in supplemented
patients were non-significantly reduced at lower cutoff
values for vitamin D insufficiency (<20 ng/mL and <12 ng/
mL) for all supplementation amounts. Conclusion: Vitamin
D supplementation in patients with vitamin D insufficiency
did not significantly reduce severe COVID-19 outcomes;
however, vitamin D supplementation was associated with
non-statistically significant reduced odds of severe COVID19 outcomes at lower cutoff values of vitamin D level. These
results demonstrate that Vitamin D supplementation may
have a protective effect against severe COVID-19 outcomes
in patients with lower baseline levels of vitamin D.
Bone and Mineral Metabolism
VITAMIN D, DIABETES AND ENERGY
METABOLISM
The Effect of Vitamin D Supplementation on Severe
COVID-19 Outcomes in Patients With Vitamin D
Insufficiency
1
Bone and Mineral Metabolism
VITAMIN D, DIABETES AND ENERGY
METABOLISM
2
Corinne Levitus, DO , Sweta Chekuri, MD , Andrei Assa,
MD2, Laurel Mohrmann, MD2, Alexandra Zindman, MD3,
Vafa Tabatabaie, MD1, Fabrizio Toscano, MD3, Masud Ahmed,
PA-C2, Sarah W. Baron, MD2.
1
Albert Einstein College of Medicine and Montefiore Medical
Center, Department of Internal Medicine, Division of
Endocrinology, Bronx, NY, USA, 2Albert Einstein College
of Medicine and Montefiore Medical Center, Department of
Medicine, Division of Hospital Medicine, Bronx, NY, USA, 3Albert
Einstein College of Medicine and Montefiore Medical Center,
Department of Internal Medicine, Residency Training Program,
Bronx, NY, USA.
The Impact of Glucose Tolerance States on Bone
Mineral Density and Fracture Rate
Maria Chang Villacreses, MD1, panadeekarn panjawatanan,
MD2, Rudruidee Karnchanasorn, MD3, Horng-Yih Ou,
MD & PhD4, Wei Feng, MD5, Raynald Samoa, MD6,
Lee-Ming Chuang, MD, PhD7, Ken C. Chiu, MD8.
1
CITY OF HOPE NATIONAL MEDICAL CENTER, Duarte, CA,
USA, 2Bassett Medical Center, Cooperstown, NY, USA, 3The
University of Kansas Medical Center, Kansas City, KS, USA,
4
National..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.